<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596033</url>
  </required_header>
  <id_info>
    <org_study_id>GEN-011-101</org_study_id>
    <nct_id>NCT04596033</nct_id>
  </id_info>
  <brief_title>TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genocea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genocea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in&#xD;
      adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each&#xD;
      patient, using the patient's own circulating immune cells. First, Genocea confirms which&#xD;
      cancer proteins are recognized already by each patient's T cells using ATLAS™. Then, immune&#xD;
      cells that recognize these cancer proteins are multiplied many times (a process called&#xD;
      PLANET™) to create a personalized GEN-011 cell therapy, which is given back to the patient in&#xD;
      one or more intravenous (IV) infusions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TiTAN-1 is an open-label, multicenter, first-in-human Phase 1 study of GEN-011 in patients&#xD;
      with melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and&#xD;
      neck (SCCHN), urothelial carcinoma (UC, bladder, ureter, urethra, or renal pelvis), renal&#xD;
      cell carcinoma (RCC), small cell lung cancer (SCLC), cutaneous squamous cell carcinoma&#xD;
      (CSCC), or anal squamous cell carcinoma (ASCC). Patients will be enrolled into one of 2&#xD;
      cohorts. One cohort will receive a multiple low dose (MLD) regimen of GEN-011 to be given&#xD;
      without lymphodepletion, and a second cohort will receive a single high dose (SHD) regimen of&#xD;
      GEN-011 after lymphodepletion. Regardless of cohort, each dose of GEN-011 will be followed by&#xD;
      a course of interleukin-2 (IL-2) as costimulatory therapy.&#xD;
&#xD;
      GEN-011 is an investigational, personalized neoantigen adoptive cell therapy (ACT) that is&#xD;
      being developed by Genocea for the treatment of adult patients with advanced solid tumors. A&#xD;
      proprietary tool developed by Genocea called ATLAS™ (Antigen Lead Acquisition System) will be&#xD;
      used to identify true immunogenic neoantigens from each patient's tumor that are recognized&#xD;
      by their own CD4 and/or CD8 T cells. ATLAS-identified neoantigens will be used to stimulate&#xD;
      and select autologous T cells collected by apheresis to generate an adoptive cell product ex&#xD;
      vivo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>2 years after first GEN-011 infusion</time_frame>
    <description>Adverse events will be graded according to the NC Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T cell responses to GEN-011</measure>
    <time_frame>2 years after first GEN-011 infusion</time_frame>
    <description>Antigen-specific immunogenicity assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>2 years after first GEN-011 infusion</time_frame>
    <description>Measured by RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years after first GEN-011 infusion</time_frame>
    <description>Length of time without disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From first GEN-011 infusion through study completion, at least 2 years</time_frame>
    <description>Length of time patient remains alive</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune cell phenotyping</measure>
    <time_frame>2 years after first GEN-011 infusion</time_frame>
    <description>Classification of peripheral immune cells via flow cytometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Epitope Spread</measure>
    <time_frame>4 weeks after first GEN-011 infusion</time_frame>
    <description>Tumor mutations will be identified by gene sequencing at multiple timepoints, and comparing the differences in mutations over time</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor infiltrating immune cell</measure>
    <time_frame>2 years after first GEN-011 infusion</time_frame>
    <description>Quantitation and phenotyping of immune cells in proximity to tumor cells using immunohistochemistry</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Melanoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Small-cell Lung Cancer</condition>
  <condition>Cutaneous Squamous Cell Carcinoma</condition>
  <condition>Anal Squamous Cell Carcinoma</condition>
  <condition>Merkel Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Multiple Low Dose (MLD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEN-011 is administered by IV infusion at 4-week intervals, up to 5 doses maximum. Each dose is followed by IL-2 administration. MLD patients will not undergo lymphodepletion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single High Dose (SHD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEN-011 is administered as a single IV infusion at the maximum available cell yield, after the patient completes a fludarabine/cyclophosphamide lymphodepletion regimen. The single GEN-011 dose is followed by IL-2 administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN-011</intervention_name>
    <description>Personalized neoantigen adoptive cell therapy (ACT)</description>
    <arm_group_label>Multiple Low Dose (MLD)</arm_group_label>
    <arm_group_label>Single High Dose (SHD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>Cytokine</description>
    <arm_group_label>Multiple Low Dose (MLD)</arm_group_label>
    <arm_group_label>Single High Dose (SHD)</arm_group_label>
    <other_name>Interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Lymphodepletion drug</description>
    <arm_group_label>Single High Dose (SHD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Lymphodepletion drug</description>
    <arm_group_label>Single High Dose (SHD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consents to study procedures&#xD;
&#xD;
          -  Diagnosis of one of the following solid tumors: cutaneous melanoma, non-small cell&#xD;
             lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial&#xD;
             carcinoma (UC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), cutaneous&#xD;
             squamous cell carcinoma (CSCC), anal squamous cell carcinoma (ASCC), merkel cell&#xD;
             carcinoma (MCC).&#xD;
&#xD;
          -  Received, been intolerant of, or been ineligible to receive standard of care treatment&#xD;
             regimen.&#xD;
&#xD;
          -  Measurable disease per RECIST criteria&#xD;
&#xD;
          -  Life expectancy &gt; 6 months and ECOG status 0 or 1&#xD;
&#xD;
          -  Capacity to tolerate lymphodepletion (SHD group only) and IL-2 therapy&#xD;
&#xD;
          -  Tumor tissue available&#xD;
&#xD;
          -  Willing to use contraceptives for 90 days after receiving GEN-011, and not currently&#xD;
             pregnant.&#xD;
&#xD;
          -  Adequate blood, liver, kidney, and lung function&#xD;
&#xD;
          -  Sufficient stimulatory neoantigens identified in ATLAS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving immunosuppressive medications&#xD;
&#xD;
          -  Serious ongoing viral, bacterial, or fungal infection&#xD;
&#xD;
          -  History of cardiac arrythmias or significant heart block&#xD;
&#xD;
          -  History of leptomeningeal carcinomatosis&#xD;
&#xD;
          -  Active autoimmune disease&#xD;
&#xD;
          -  Portal vein thrombosis&#xD;
&#xD;
          -  Malignant disease other than those treated in this study&#xD;
&#xD;
          -  Receiving other investigational anti-cancer therapy&#xD;
&#xD;
          -  Prior stem cell or solid organ transplant&#xD;
&#xD;
          -  Primary immune deficiency disease&#xD;
&#xD;
          -  Significant ongoing toxicities from prior therapies&#xD;
&#xD;
          -  A history of allergic reaction to sulfur derivatives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Davis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Genocea Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Hernandez</last_name>
    <phone>617-876-8191</phone>
    <email>richard.hernandez@genocea.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Myers, RN</last_name>
      <email>sheila.myers@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Jiaxin Niu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Benjamin Creelan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Bishop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Utkarsh Acharya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianne Bodin</last_name>
      <email>bb2895@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Stein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Aggen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ask Sarah</last_name>
      <phone>615-339-4214</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Melissa L Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debora Clay</last_name>
      <phone>713-745-0294</phone>
      <email>daclay@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Maura Gillison, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Personalized</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Personal</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Lung</keyword>
  <keyword>Bladder</keyword>
  <keyword>Cancer</keyword>
  <keyword>Kidney</keyword>
  <keyword>Anal</keyword>
  <keyword>Squamous</keyword>
  <keyword>TiTAN</keyword>
  <keyword>ATLAS</keyword>
  <keyword>PLANET</keyword>
  <keyword>TiTAN-1</keyword>
  <keyword>Autologous</keyword>
  <keyword>Neoantigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

